WHO en­dors­es GSK's do­lute­gravir for HIV; Syapse col­lab­o­rates with Pfiz­er on RWE

→ GSK is get­ting a big en­dorse­ment from the World Health Or­ga­ni­za­tion. The WHO is rec­om­mend­ing that their drug do­lute­gravir (DTG) should be the stan­dard ther­a­py in front­line and sec­ond-line set­tings for HIV pa­tients in up­dat­ed 2019 guide­lines. They note: “DTG is a drug that is more ef­fec­tive, eas­i­er to take and has few­er side ef­fects than al­ter­na­tive drugs that are cur­rent­ly used. DTG al­so has a high ge­net­ic bar­ri­er to de­vel­op­ing drug re­sis­tance, which is im­por­tant giv­en the ris­ing trend of re­sis­tance to EFV and nevi­rap­ine-based reg­i­mens. In 2019, 12 out of 18 coun­tries sur­veyed by WHO re­port­ed pre-treat­ment drug re­sis­tance lev­els ex­ceed­ing the rec­om­mend­ed thresh­old of 10%.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER